FGFR2 and gastric cancer: Favourable safety and activity were observed in a Phase 1 study and a Phase 3 study (FIGHT) evaluating standard of care chemotherapy in combination with FPA144 or placebo as first-line therapy for patients with gastric cancer overexpressing FGFR2 and is currently open for enrolment (NCT03694522).71